Rogosin Institute Patients Have Superior Health Outcomes

Study shows dialysis patients fare better, have more access to transplants
NEW YORK--(Business Wire)--
Dialysis patients at The Rogosin Institute experience better health outcomes and
have better access to kidney transplants than patients nationwide, a study of
patient outcomes has shown. According to the 2009 national Dialysis Facility
Report of all dialysis centers, Rogosin patients were shown to live longer, have
fewer hospitalizations and receive more transplants than patients nationally.

At both one- and three-year milestones, Rogosin patients at its Manhattan
facility showed better outcomes than those on dialysis in centers nationally.
The study showed that there were 52 percent fewer deaths of patients during
their first year of dialysis. For the three-year period between 2005 and 2008,
the Rogosin Institute dialysis patients had 20 percent fewer deaths than would
be expected.

Rogosin dialysis patients had 18 percent fewer hospital admissions and twice as
many Rogosin patients received kidney transplants compared to patients
nationally. Forty-nine percent of Rogosin patients were on a transplant waiting
list, compared to 21 percent of patients at centers nationally. The Rogosin
Dialysis Centers in Queens and Brooklyn also had excellent results.

The dialysis center Facility Report utilizes data from the Centers for Medicare
and Medicaid and was compiled by the University of Michigan Epidemiology and
Cost Center for the year 2009. The report provides dialysis facilities, state
surveyors and regions with valuable information on patient characteristics,
treatment patterns, hospitalization, mortality and transplantation patterns in
their facilities. The report can be found at www.medicare.gov/Dialysis.

"The data show what we have known to be the case: that Rogosin patients receive
outstanding care that translates into better health outcomes," said Barry Smith,
MD, Director of The Rogosin Institute. "Rogosin`s state of the art dialysis,
superior clinical care and aggressive transplantation models add up to the
extremely high quality of care that our patients have come to expect."

The Rogosin Institute is an independent not-for-profit treatment and research
center affiliated with NewYork-Presbyterian Hospital (NYPH), Weill Cornell
Medical College and a member of NewYork-Presbyterian Healthcare System. It is
one of the nation`s leading treatment centers for kidney disease, including
research, dialysis, transplantation, and the treatment of diseases that
contribute to kidney failure, such as hypertension and lipid disorders. Rogosin
provides the programs that propelled NYPH to a #2 ranking nationally in the
treatment of kidney disease.*

*Best Hospitals, ranked by USNews & World Report.

The Rogosin Institute
Susan Spiegel, 212-746-1552
Development Office

Copyright Business Wire 2009